Viking Therapeutics Stock Buy or Sell on Dip
· news
The Siren Song of Weight-Loss Stocks: A Cautionary Tale for Investors
The allure of Viking Therapeutics’ VK2735, a potential blockbuster weight-loss drug, has sent Wall Street analysts into a frenzy. With its stock plummeting to what some see as a buying opportunity, investors are being asked to take a leap of faith on this company’s lead drug candidate.
Wall Street’s consensus price target for Viking Therapeutics is $91, representing a 150% return from its current price. This optimism stems from VK2735’s potential in the lucrative weight-loss market, where investors seek the next big thing. However, history has shown that this sector is not immune to hype and disappointment.
In recent years, several promising weight-loss drugs have failed to deliver on their promise after making it through clinical trials. Orexigen’s Contrave and Arena Pharmaceuticals’ Belviq are prime examples of companies that touted revolutionary treatments for obesity but ultimately faltered. VK2735 has already shown some red flags, including questionable tolerability data from the oral phase 2 trial.
The company’s lead drug candidate has a steeper velocity of weight loss than rival drugs in phase 2 trials, which might make it seem promising on paper. However, past performance is not indicative of future results. The real question is whether Viking Therapeutics can replicate its success in the higher-stakes world of phase 3 trials.
The maintenance dosing trial, scheduled to provide some answers in the coming months, won’t be enough to fully prove VK2735’s efficacy until the phase 3 results are released – a long way off in late 2027 and 2028. Meanwhile, investors are being asked to navigate the complex regulatory landscape and take a leap of faith on Viking Therapeutics’ ability to execute.
Even Wall Street’s most enthusiastic analysts caution investors to wait until the maintenance dosing trial results are in before making a move. Established players in this space might be worth considering, as the weight-loss sector is a high-risk, high-reward game. Investors would do well to remember Warren Buffett’s words: “Price is what you pay. Value is what you get.” In this case, the price might be tempting, but the value remains uncertain – at least until those phase 3 results are in.
The question now is whether Viking Therapeutics can deliver on its promise and justify the faith that investors have placed in it. Until then, it’s best to approach this stock with a healthy dose of skepticism and caution – lest we forget the lessons of history and the risks of investing in unproven biotech companies.
Reader Views
- RJReporter J. Avery · staff reporter
Viking Therapeutics' VK2735 is being touted as the next big thing in weight-loss treatments, but investors would do well to remember that hype often precedes disappointment in this sector. A key concern I haven't seen addressed is the potential for regulatory pushback due to VK2735's mechanism of action, which some might argue infringes on existing patent landscapes. If Viking Therapeutics can't navigate these complexities, its high-flying stock could quickly come crashing back down.
- CSCorrespondent S. Tan · field correspondent
Investors should exercise caution when chasing the next big thing in weight-loss stocks. While VK2735's impressive phase 2 results are certainly attention-grabbing, history has shown that success at this stage is no guarantee of future performance. A more nuanced approach would be to focus on the company's cash burn rate and management team's track record of executing on clinical trials. With Viking Therapeutics' already thin profit margins and looming regulatory hurdles, a closer look at their financials and leadership might provide a more accurate picture of their chances for success.
- CMColumnist M. Reid · opinion columnist
The weight-loss market's siren song is luring investors with promises of blockbuster returns, but Wall Street's history of hype and disappointment should give pause. While VK2735's impressive weight loss velocity may be a selling point, what about the drug's potential long-term side effects? The article glosses over this critical concern, and investors would do well to remember that a speedy weight loss can often mask underlying issues. Until more is known about VK2735's safety profile, it's wise to exercise caution and consider waiting for phase 3 results before taking the plunge.